SEC Form 4 · accession 0001209191-17-061542
Audentes Therapeutics, Inc. · BOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mary Newman
Officer — SVP, Regulatory Affairs
Period of report
Nov 16, 2017
Accepted (ET)
Nov 17, 2017 · 5:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628738
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 16, 2017 | M | 5,740 | $2.19 | A | 5,740 | D | |
| Common StockF2 | Nov 16, 2017 | S | 5,740 | $26.4866 | D | 0 | D | |
| Common Stock | Nov 16, 2017 | M | 4,260 | $2.19 | A | 4,260 | D | |
| Common StockF3 | Nov 16, 2017 | S | 4,260 | $27.3104 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $2.19 | Nov 16, 2017 | M | 10,000 | D | — | Feb 4, 2025 | Common Stock | 10,000 | 33,817 | D |
| Stock Option (right to buy)F5 | $27.39 | Nov 16, 2017 | A | 50,000 | A | — | Nov 16, 2021 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- F2Represents the weighted average sale price. The lowest price at which shares were sold was $25.96 and the highest price at which shares were sold was $26.90. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
- F3Represents the weighted average sale price. The lowest price at which shares were sold was $26.97 and the highest price at which shares were sold was $27.51.
- F4The option vested as to 25% of the total shares on October 1, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on October 1, 2018, subject to the reporting person's provision of service to the issuer on each vesting date.
- F5The option vests as to 2.0833% of the total shares monthly, beginning December 16, 2017, with 100% of the total shares vested and exercisable on November 16, 2021, subject to the reporting person's provision of service to the issuer on each vesting date.